Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. [electronic resource]
Producer: 20101028Description: 1312-9 p. digitalISSN:- 1474-547X
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- genetics
- Acute Coronary Syndrome -- drug therapy
- Angioplasty, Balloon, Coronary
- Aryl Hydrocarbon Hydroxylases -- genetics
- Cardiovascular Diseases -- etiology
- Clopidogrel
- Cytochrome P-450 CYP2C19
- Female
- Genetic Variation
- Genotype
- Humans
- Male
- Middle Aged
- Pharmacogenetics
- Piperazines -- adverse effects
- Platelet Aggregation -- drug effects
- Platelet Aggregation Inhibitors -- adverse effects
- Polymorphism, Single Nucleotide
- Prasugrel Hydrochloride
- Randomized Controlled Trials as Topic
- Thiophenes -- adverse effects
- Ticlopidine -- adverse effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.